Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417079 · ClinicalTrials.gov registry record · Phase 3
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
A Phase 3 study of Neoplasms and Prostatic Neoplasms, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 755
- Enrollment target
- 20
- Study locations
NCT00417079 is a Phase 3 study of Neoplasms and Prostatic Neoplasms that has completed, run by Sanofi. The registered enrollment target is 755 participants, below the 1,617-participant average among 158 other Neoplasms trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00417079, a Phase 3 study of Neoplasms and Prostatic Neoplasms, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 755 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cabazitaxel (XRP6258) (RPR116258)
- DRUG mitoxantrone
Study Locations (20)
Other
- sanofi-aventis Argentina - Buenos Aires
- sanofi-aventis Belgium - Diegem
- sanofi-aventis Brazil - São Paulo
- sanofi-aventis Chile - Santiago
- sanofi-aventis Czech Republic - Prague
- sanofi-aventis Denmark - Hørsholm
- sanofi-aventis Finland - Helsinki
- sanofi-aventis France - Paris
- sanofi-aventis Germany - Berlin
- Sanofi-Aventis Hungaria - Budapest
- sanofi-aventis India - Mumbai
- sanofi-aventis Italy - Milan
- sanofi-aventis Mexico - México
- sanofi-aventis Netherlands - Gouda
- sanofi-aventis Russia - Moscow
- sanofi-aventis Singapore - Singapore
- sanofi-aventis Slovakia - Bratislava
- sanofi-aventis South Africa - Midrand
New Jersey
- sanofi-aventis US - Bridgewater
Quebec
- sanofi-aventis Canada - Laval
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417079
The ClinicalTrials.gov registry entry for NCT00417079 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 755 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,617-participant average among 158 other Neoplasms trials with a reported enrollment target (53% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.
NCT00417079 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, New Jersey, Quebec.
Frequently Asked Questions
What is clinical trial NCT00417079 about?
NCT00417079 is a clinical study titled "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer". This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall...
What is the current status of trial NCT00417079?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 755 participants. The study started on 2007-01. Estimated completion is 2009-09.
What conditions does trial NCT00417079 study?
This clinical trial studies the following conditions: Neoplasms, Prostatic Neoplasms.
What interventions are being tested in trial NCT00417079?
The interventions under investigation include: prednisone (DRUG), cabazitaxel (XRP6258) (RPR116258) (DRUG), mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT00417079?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00417079 being conducted?
This trial has 20 study locations across New Jersey, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
COMPLETED · Phase 3
-
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.